Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 9 of 9 entries
Sorted by: Best Match Show Resources per page
The European LEMS Registry: Baseline Demographics and Treatment Approaches.

Neurology and therapy

Mantegazza R, Meisel A, Sieb JP, Le Masson G, Desnuelle C, Essing M.
PMID: 26525537
Neurol Ther. 2015 Dec;4(2):105-24. doi: 10.1007/s40120-015-0034-0. Epub 2015 Nov 02.

INTRODUCTION: Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder affecting the neuromuscular junction, clinically characterized by proximal muscle weakness and autonomic changes. LEMS is often associated with an underlying tumor (paraneoplastic form) but also occurs in the absence...

Cite
Mantegazza R, Meisel A, Sieb JP, et al. The European LEMS Registry: Baseline Demographics and Treatment Approaches. Neurol Ther. 2015;4(2):105-24doi: 10.1007/s40120-015-0034-0.
Mantegazza, R., Meisel, A., Sieb, J. P., Le Masson, G., Desnuelle, C., & Essing, M. (2015). The European LEMS Registry: Baseline Demographics and Treatment Approaches. Neurology and therapy, 4(2), 105-24. https://doi.org/10.1007/s40120-015-0034-0
Mantegazza, Renato, et al. "The European LEMS Registry: Baseline Demographics and Treatment Approaches." Neurology and therapy vol. 4,2 (2015): 105-24. doi: https://doi.org/10.1007/s40120-015-0034-0
Mantegazza R, Meisel A, Sieb JP, Le Masson G, Desnuelle C, Essing M. The European LEMS Registry: Baseline Demographics and Treatment Approaches. Neurol Ther. 2015 Dec;4(2):105-24. doi: 10.1007/s40120-015-0034-0. Epub 2015 Nov 02. PMID: 26525537; PMCID: PMC4685864.
Copy Download .nbib Format: NLM
Recent Advances and Therapeutic Options in Lambert-Eaton Myasthenic Syndrome.

Cureus

Anwar A, Saleem S, Ahmed MF, Ashraf S, Ashraf S.
PMID: 31637147
Cureus. 2019 Aug 21;11(8):e5450. doi: 10.7759/cureus.5450.

Lambert-Eaton Myasthenic Syndrome (LEMS) is an autoimmune-mediated neurological disorder that manifests as muscle fatigue, diminished tendon reflexes, with symptoms of cholinergic overactivity. It can be associated with certain neoplastic conditions, the most common being small cell lung carcinoma (SCLC)....

Cite
Anwar A, Saleem S, Ahmed MF, et al. Recent Advances and Therapeutic Options in Lambert-Eaton Myasthenic Syndrome. Cureus. 2019;11(8):e5450doi: 10.7759/cureus.5450.
Anwar, A., Saleem, S., Ahmed, M. F., Ashraf, S., & Ashraf, S. (2019). Recent Advances and Therapeutic Options in Lambert-Eaton Myasthenic Syndrome. Cureus, 11(8), e5450. https://doi.org/10.7759/cureus.5450
Anwar, Arsalan, et al. "Recent Advances and Therapeutic Options in Lambert-Eaton Myasthenic Syndrome." Cureus vol. 11,8 (2019): e5450. doi: https://doi.org/10.7759/cureus.5450
Anwar A, Saleem S, Ahmed MF, Ashraf S, Ashraf S. Recent Advances and Therapeutic Options in Lambert-Eaton Myasthenic Syndrome. Cureus. 2019 Aug 21;11(8):e5450. doi: 10.7759/cureus.5450. PMID: 31637147; PMCID: PMC6799875.
Copy Download .nbib Format: NLM
Lambert-Eaton myasthenic syndrome revealed after surgery of lung adenocarcinoma.

Asian cardiovascular & thoracic annals

Kabiri EH, Hammoumi ME, Sbitti Y.
PMID: 34605270
Asian Cardiovasc Thorac Ann. 2021 Oct 04;2184923211051796. doi: 10.1177/02184923211051796. Epub 2021 Oct 04.

We report a very rare case of cT1N0M0 lung adenocarcinoma reveling Lambert-Eaton myasthenic syndrome (LEMS). A 69-year-old nonsmoking woman, with several comorbidities consulted for cough and dyspnea. Chest radiograph and CT scanning detected a left lower lobe mass; Needle...

Cite
Kabiri EH, Hammoumi ME, Sbitti Y. Lambert-Eaton myasthenic syndrome revealed after surgery of lung adenocarcinoma. Asian Cardiovasc Thorac Ann. 2021;2184923211051796doi: 10.1177/02184923211051796.
Kabiri, E. H., Hammoumi, M. E., & Sbitti, Y. (2021). Lambert-Eaton myasthenic syndrome revealed after surgery of lung adenocarcinoma. Asian cardiovascular & thoracic annals, 2184923211051796. https://doi.org/10.1177/02184923211051796
Kabiri, El Hassane, et al. "Lambert-Eaton myasthenic syndrome revealed after surgery of lung adenocarcinoma." Asian cardiovascular & thoracic annals vol. (2021): 2184923211051796. doi: https://doi.org/10.1177/02184923211051796
Kabiri EH, Hammoumi ME, Sbitti Y. Lambert-Eaton myasthenic syndrome revealed after surgery of lung adenocarcinoma. Asian Cardiovasc Thorac Ann. 2021 Oct 04;2184923211051796. doi: 10.1177/02184923211051796. Epub 2021 Oct 04. PMID: 34605270.
Copy Download .nbib Format: NLM
Lambert-Eaton myasthenic syndrome revealed after surgery of lung adenocarcinoma.

Asian cardiovascular & thoracic annals

Kabiri EH, Hammoumi ME, Sbitti Y.
PMID: 34605270
Asian Cardiovasc Thorac Ann. 2021 Oct 04;2184923211051796. doi: 10.1177/02184923211051796. Epub 2021 Oct 04.

We report a very rare case of cT1N0M0 lung adenocarcinoma reveling Lambert-Eaton myasthenic syndrome (LEMS). A 69-year-old nonsmoking woman, with several comorbidities consulted for cough and dyspnea. Chest radiograph and CT scanning detected a left lower lobe mass; Needle...

Cite
Kabiri EH, Hammoumi ME, Sbitti Y. Lambert-Eaton myasthenic syndrome revealed after surgery of lung adenocarcinoma. Asian Cardiovasc Thorac Ann. 2021;2184923211051796doi: 10.1177/02184923211051796.
Kabiri, E. H., Hammoumi, M. E., & Sbitti, Y. (2021). Lambert-Eaton myasthenic syndrome revealed after surgery of lung adenocarcinoma. Asian cardiovascular & thoracic annals, 2184923211051796. https://doi.org/10.1177/02184923211051796
Kabiri, El Hassane, et al. "Lambert-Eaton myasthenic syndrome revealed after surgery of lung adenocarcinoma." Asian cardiovascular & thoracic annals vol. (2021): 2184923211051796. doi: https://doi.org/10.1177/02184923211051796
Kabiri EH, Hammoumi ME, Sbitti Y. Lambert-Eaton myasthenic syndrome revealed after surgery of lung adenocarcinoma. Asian Cardiovasc Thorac Ann. 2021 Oct 04;2184923211051796. doi: 10.1177/02184923211051796. Epub 2021 Oct 04. PMID: 34605270.
Copy Download .nbib Format: NLM
Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate.

Pharmacology research & perspectives

Haroldsen PE, Garovoy MR, Musson DG, Zhou H, Tsuruda L, Hanson B, O'Neill CA.
PMID: 25692017
Pharmacol Res Perspect. 2015 Feb;3(1):e00099. doi: 10.1002/prp2.99. Epub 2014 Dec 09.

The clinical use of amifampridine phosphate for neuromuscular junction disorders is increasing. The metabolism of amifampridine occurs via polymorphic aryl N-acetyltransferase (NAT), yet its pharmacokinetic (PK) and safety profiles, as influenced by this enzyme system, have not been investigated....

Cite
Haroldsen PE, Garovoy MR, Musson DG, et al. Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate. Pharmacol Res Perspect. 2014;3(1):e00099doi: 10.1002/prp2.99.
Haroldsen, P. E., Garovoy, M. R., Musson, D. G., Zhou, H., Tsuruda, L., Hanson, B., & O'Neill, C. A. (2015). Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate. Pharmacology research & perspectives, 3(1), e00099. https://doi.org/10.1002/prp2.99
Haroldsen, Peter E, et al. "Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate." Pharmacology research & perspectives vol. 3,1 (2015): e00099. doi: https://doi.org/10.1002/prp2.99
Haroldsen PE, Garovoy MR, Musson DG, Zhou H, Tsuruda L, Hanson B, O'Neill CA. Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate. Pharmacol Res Perspect. 2015 Feb;3(1):e00099. doi: 10.1002/prp2.99. Epub 2014 Dec 09. PMID: 25692017; PMCID: PMC4317230.
Copy Download .nbib Format: NLM
Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine.

Neuropsychiatric disease and treatment

Lindquist S, Stangel M.
PMID: 21822385
Neuropsychiatr Dis Treat. 2011;7:341-9. doi: 10.2147/NDT.S10464. Epub 2011 May 30.

In Lambert-Eaton myasthenic syndrome (LEMS), antibodies against presynaptic voltage-gated calcium channels reduce the quantal release of acetylcholine, causing muscle weakness and autonomic dysfunction. More than half of the affected patients have associated small cell lung cancer, and thorough screening...

Cite
Lindquist S, Stangel M. Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatr Dis Treat. 2011;7:341-9doi: 10.2147/NDT.S10464.
Lindquist, S., & Stangel, M. (2011). Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatric disease and treatment, 7341-9. https://doi.org/10.2147/NDT.S10464
Lindquist, Sabine, and Stangel, Martin. "Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine." Neuropsychiatric disease and treatment vol. 7 (2011): 341-9. doi: https://doi.org/10.2147/NDT.S10464
Lindquist S, Stangel M. Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatr Dis Treat. 2011;7:341-9. doi: 10.2147/NDT.S10464. Epub 2011 May 30. PMID: 21822385; PMCID: PMC3148925.
Copy Download .nbib Format: NLM
Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover study.

SAGE open medicine

Bonanno S, Pasanisi MB, Frangiamore R, Maggi L, Antozzi C, Andreetta F, Campanella A, Brenna G, Cottini L, Mantegazza R.
PMID: 30574306
SAGE Open Med. 2018 Dec 17;6:2050312118819013. doi: 10.1177/2050312118819013. eCollection 2018.

OBJECTIVE: The aim of this study is to determine the safety and the efficacy of amifampridine phosphate in muscle-specific kinase antibody-positive myasthenia gravis, in a 1:1 randomized, double-blind, placebo-controlled, switchback, double crossover study.METHODS: Eligible patients had muscle-specific kinase myasthenia...

Cite
Bonanno S, Pasanisi MB, Frangiamore R, et al. Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover study. SAGE Open Med. 2018;6:2050312118819013doi: 10.1177/2050312118819013.
Bonanno, S., Pasanisi, M. B., Frangiamore, R., Maggi, L., Antozzi, C., Andreetta, F., Campanella, A., Brenna, G., Cottini, L., & Mantegazza, R. (2018). Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover study. SAGE open medicine, 62050312118819013. https://doi.org/10.1177/2050312118819013
Bonanno, Silvia, et al. "Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover study." SAGE open medicine vol. 6 (2018): 2050312118819013. doi: https://doi.org/10.1177/2050312118819013
Bonanno S, Pasanisi MB, Frangiamore R, Maggi L, Antozzi C, Andreetta F, Campanella A, Brenna G, Cottini L, Mantegazza R. Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover study. SAGE Open Med. 2018 Dec 17;6:2050312118819013. doi: 10.1177/2050312118819013. eCollection 2018. PMID: 30574306; PMCID: PMC6299310.
Copy Download .nbib Format: NLM
Probing the Strength and Mechanism of Binding Between Amifampridine and Calf Thymus DNA.

DNA and cell biology

Sharifinia S, Hajibabaei F, Salehzadeh S, Hosseinpour Moghadam N, Khazalpour S.
PMID: 33090906
DNA Cell Biol. 2020 Oct 22; doi: 10.1089/dna.2020.5618. Epub 2020 Oct 22.

In this work, we have investigated the strength and mechanism of amifampridine (3,4-Diaminopyridine/3,4-DAP) interaction with calf thymus DNA (ct-DNA). The existence and the strength of interaction are evaluated using circular dichroism (CD), UV-vis absorption, and differential pulse voltammogram studies....

Cite
Sharifinia S, Hajibabaei F, Salehzadeh S, et al. Probing the Strength and Mechanism of Binding Between Amifampridine and Calf Thymus DNA. DNA Cell Biol. 2020;doi: 10.1089/dna.2020.5618.
Sharifinia, S., Hajibabaei, F., Salehzadeh, S., Hosseinpour Moghadam, N., & Khazalpour, S. (2020). Probing the Strength and Mechanism of Binding Between Amifampridine and Calf Thymus DNA. DNA and cell biology, . https://doi.org/10.1089/dna.2020.5618
Sharifinia, Samira, et al. "Probing the Strength and Mechanism of Binding Between Amifampridine and Calf Thymus DNA." DNA and cell biology vol. (2020). doi: https://doi.org/10.1089/dna.2020.5618
Sharifinia S, Hajibabaei F, Salehzadeh S, Hosseinpour Moghadam N, Khazalpour S. Probing the Strength and Mechanism of Binding Between Amifampridine and Calf Thymus DNA. DNA Cell Biol. 2020 Oct 22; doi: 10.1089/dna.2020.5618. Epub 2020 Oct 22. PMID: 33090906.
Copy Download .nbib Format: NLM
Neuromuscular junction disorders beyond myasthenia gravis.

Current opinion in neurology

Oh SJ.
PMID: 34914667
Curr Opin Neurol. 2021 Oct 01;34(5):648-657. doi: 10.1097/WCO.0000000000000972.

PURPOSE OF REVIEW: To give an overview of the recent data on three autoimmune neuromuscular junction disorders with the recent Food Drug Administration (FDA) approval of amifampridine [3,4-Diaminopyridine (3,4-DAP) and 3,4-diaminopyridine phosphate (3,4-DAPP) for the treatment of Lambert-Eaton myasthenic...

Cite
Oh SJ. Neuromuscular junction disorders beyond myasthenia gravis. Curr Opin Neurol. 2021;34(5):648-657doi: 10.1097/WCO.0000000000000972.
Oh, S. J. (2021). Neuromuscular junction disorders beyond myasthenia gravis. Current opinion in neurology, 34(5), 648-657. https://doi.org/10.1097/WCO.0000000000000972
Oh, Shin J. "Neuromuscular junction disorders beyond myasthenia gravis." Current opinion in neurology vol. 34,5 (2021): 648-657. doi: https://doi.org/10.1097/WCO.0000000000000972
Oh SJ. Neuromuscular junction disorders beyond myasthenia gravis. Curr Opin Neurol. 2021 Oct 01;34(5):648-657. doi: 10.1097/WCO.0000000000000972. PMID: 34914667.
Copy Download .nbib Format: NLM
Showing 1 to 9 of 9 entries